Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 9/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094966 | 0.90 | KDM1A (0.54) | KDM1ARIPK1CCR5MAOARORC | |
| SCHEMBL1105747 | 0.90 | KDM1A (0.54) | KDM1ARIPK1CCR5MAOARORC | |
| SCHEMBL4094920 | 0.88 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL4105850 | 0.88 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL4108855 | 0.88 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL1105753 | 0.87 | RIPK1 (0.42) | KDM1ARIPK1CCR5 | |
| SCHEMBL14920777 | 0.85 | CCR5 (0.45) | KDM1ACCR5MAOAALDH1A1POLB | |
| SCHEMBL1105721 | 0.84 | BRD4 (0.41) | KDM1ARIPK1CCR5RBP4 | |
| SCHEMBL10841129 | 0.79 | SLC6A2 (0.49) | KDM1ACCR5 | |
| SCHEMBL1096468 | 0.79 | KDM1A (0.54) | KDM1ARIPK1MAOARORCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | KDM1A 2816/4885RIPK1 2346/4885CCR5 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.